AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 3 - (NewsRx.com & NewsRx.net) --
CryoLife, Inc. announced that its wholly owned subsidiary, AuraZyme Pharmaceuticals, Inc., presented results of animal studies on its A-Z-CINN Linker for targeted delivery of anticancer chemotherapy drugs.
The presentation was made at the First International Congress on Monoclonal Antibodies held in Banff, Alberta, Canada, August 30-September 2, 2001.
The multidiscipline Congress was organized to provide scientists or researchers from leading biotechnology companies and university laboratories with a forum on new developments using monoclonal antibodies in the treatment of both solid tumors and hematological malignancies.
Kirby S. Black, PhD, CryoLife, Inc., and AuraZyme, presented the results of the initial study on mice in treating primary and metastatic cancers. The data demonstrated a significant reduction in tumor mass with a single treatment using an A-Z-CINN immunoconjugate of commercially available cancer drugs. Groups receiving A-Z-CINN targeted therapy showed rapid tumor reduction within seven days of treatment and as much 60% shrinkage by the end of the study (28 days). Groups receiving systemic therapy of unlinked chemo drugs had limited tumor response rates.
AuraZyme technology, A-Z-CINN Linker, represents an opportunity to create a revolutionary ...
Source: HighBeam Research, Immunoconjugate Enhances Chemotherapy Effectiveness.(Brief Article)